Press Releases

Press Releases

Filters
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Provides Pipeline Update on Four Regulatory Milestones
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Displaying 1 - 10 of 184